- Home
- TYRA vs UHT Comparison
TYRA vs UHT Comparison
Compare TYRA & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- UHT
- Stock Information
- Founded
- TYRA 2018
- UHT 1986
- Country
- TYRA United States
- UHT United States
- Employees
- TYRA N/A
- UHT N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- UHT Real Estate Investment Trusts
- Sector
- TYRA Health Care
- UHT Real Estate
- Exchange
- TYRA Nasdaq
- UHT Nasdaq
- Market Cap
- TYRA 571.9M
- UHT 566.7M
- IPO Year
- TYRA 2021
- UHT N/A
- Fundamental
- Price
- TYRA $12.45
- UHT $41.64
- Analyst Decision
- TYRA Strong Buy
- UHT
- Analyst Count
- TYRA 8
- UHT 0
- Target Price
- TYRA $31.00
- UHT N/A
- AVG Volume (30 Days)
- TYRA 235.9K
- UHT 58.7K
- Earning Date
- TYRA 11-06-2025
- UHT 10-23-2025
- Dividend Yield
- TYRA N/A
- UHT 7.05%
- EPS Growth
- TYRA N/A
- UHT N/A
- EPS
- TYRA N/A
- UHT 1.30
- Revenue
- TYRA N/A
- UHT $99,952,000.00
- Revenue This Year
- TYRA N/A
- UHT $3.87
- Revenue Next Year
- TYRA N/A
- UHT N/A
- P/E Ratio
- TYRA N/A
- UHT $31.61
- Revenue Growth
- TYRA N/A
- UHT 0.31
- 52 Week Low
- TYRA $6.42
- UHT $34.56
- 52 Week High
- TYRA $29.60
- UHT $47.30
- Technical
- Relative Strength Index (RSI)
- TYRA 58.97
- UHT 61.31
- Support Level
- TYRA $11.70
- UHT $40.59
- Resistance Level
- TYRA $12.55
- UHT $42.08
- Average True Range (ATR)
- TYRA 0.68
- UHT 0.58
- MACD
- TYRA -0.03
- UHT 0.16
- Stochastic Oscillator
- TYRA 52.50
- UHT 80.82
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.